First orbital rocket launched from Europe crashes into sea - but company says test 'met all expectations'
The first orbital rocket launched from mainland Europe took off from Norway on Sunday - but crashed into the sea and exploded 40 seconds later.
The unmanned Spectrum rocket blasted off from the Arctic Andoeya Spaceport, on Sunday at 12.30pm local time before it was terminated less than a minute later.
Isar Aerospace, the German company that built the rocket, had warned that the launch could end prematurely. It maintained that despite being short, the flight had produced extensive data that its team could learn from.
"Our first test flight met all our expectations, achieving a great success," Daniel Metzler, Isar's chief executive and co-founder, said.
"We had a clean lift-off, 30 seconds of flight and even got to validate our flight termination system."
Spectrum is a two-stage launch vehicle specifically designed to put small and medium satellites into orbit.
Its maiden voyage was aimed at kickstarting satellite launches from Europe.
Several European nations, including the UK and Sweden, have said they want to be an active player in the growing market of commercial space missions.
Big global companies already ahead in the satellite launch game include Elon Musk's SpaceX, which launches from the US, and French company ArianeGroup, a joint venture between Airbus and Safran that uses a spaceport in South America's French Guiana.
Mr Musk's SpaceX also operates the Starlink satellite service, a communications network that can provide much of the globe with access to the internet.
Germany's BDLI aerospace industries association said Isar's first flight would lead to further progress.
BDLI managing director, Marie-Christine von Hahn, said: "Europe urgently needs to ensure its sovereignty in space. Elon Musk's Starlink is not without alternatives - nor should it be."
Read more from Sky News:
Sweden, with its Esrange launch site, and Britain with its SaxaVord Spaceport in the Scottish Shetland Islands, are the nearest rivals to the Norwegian site, all of which aim to give Europe greater autonomy in space flights.
SaxaVord, which suffered a setback when a rocket engine exploded during a test last year, is planning its first satellite launch later this year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Ukraine plots fracking revolution
Ukraine is working to unleash natural gas fracking with the goal of becoming a major exporter and revolutionising Europe's energy market. In plans critical to Volodymyr Zelensky's hopes of a post-war economic recovery, ministers in Kyiv are scrambling to lure private investment and gain access to new drilling technology to access the country's vast untapped shale gas resources. According to sources close to Kyiv, officials are racing to attract 'foreign technology and highly experienced subsoil users', with a focus on unconventional shale resources in western Ukraine. The hunt for cash - as revealed by the independent news platform Energy Flux - is being conducted in parallel to the rare earth minerals deal struck between Donald Trump and President Zelensky in April, which will allow the US to exploit Ukraine's natural resources, including aluminium, graphite, oil and natural gas. The priority is to rapidly revitalise Ukraine's ailing gas sector after a gruelling winter saw roughly 40pc of production capacity taken out by a fierce Russian campaign of drone and missile strikes. The attacks forced Ukraine to draw heavily on its gas stocks, which ended winter almost entirely depleted. But Ukraine's Ministry of Energy believes it is possible to refill the country's cavernous underground storage facilities and even produce a surplus for export 'within 18 months', according to a senior government source. Ukraine already has some experience with advanced drilling technology for old wells and has since carried out experimental trials that 'confirm its potential' for fracking, they said. However, to unlock Ukraine's shale reserves, the country needs to attract more investment and newer kit, primarily from America. 'Development and production can be quickly developed using available gas infrastructure with connections to the EU gas market that make it very attractive,' the source added. 'Ukraine has enough deposits of traditional gas to cover its own consumption and to become a net exporter, and shale gas production has quite a profound effect on its development.' Such a turnaround would help transform the fortunes of Europe's energy markets, which remain on edge following the loss of Russian pipeline gas exports via Ukraine at the start of 2025. Refilling Ukraine's depleted gas storage – the largest in Europe, at 32bn cubic metres – is one of the main factors tightening energy markets in Central and Eastern Europe ahead of next winter. Ukraine's gas stocks are today just 7pc full compared to the EU average of 50pc. Efforts to pipe natural gas from Southern and Eastern Europe into Ukraine have also been thwarted by red tape and a lack of market cohesion. However, if Ukraine could unleash its own shale revolution and create a surplus for export, the need to keep pumping European gas into Ukraine would effectively disappear overnight. It would also help reduce Europe's reliance on costly liquefied natural gas (LNG) supplies from overseas. Gas-starved Europe leaned heavily on LNG after Gazprom, the Kremlin-backed energy giant, halted exports to the EU following Vladimir Putin's full-scale invasion of Ukraine in 2022. Ukrainian shale gas exports, if scaled up quickly, would erase a large chunk of European energy demand currently being met by LNG, potentially sparking a sharp drop in energy prices around the world. However, Kyiv's proposed fracking revolution hinges largely on the country's ability to secure overseas investment. Officials from Ukraine's Ministry of Energy are tapping Western diplomatic ties to find private capital funds with a high tolerance for risk to bankroll drilling and bring in technology partners. A senior government team attended the Baku Energy Forum in Azerbaijan last week in part to promote Ukraine's potential as a shale hub. Speaking at the event, one high-ranking statesman said the Lviv-Lublin geological area that straddles the Ukraine-Poland border is 'superior on the Ukrainian side' thanks to higher porosity and lower clay content, making it 'better for fracking'. The most promising prospect is the Oleska (Olesskaya) shale block, which contains an estimated 0.8 to 1.5 trillion cubic metres of shale gas resources – enough to meet Ukraine's domestic needs for decades. How much of this resource is economically recoverable is an open question. Chevron walked away from a 50pc interest in the Oleska project in 2014 before drilling could begin. Chevron's stated reason for leaving was not because of political instability or lack of resources, but rather Kyiv's failure to enact specific tax reforms necessary to enable shale gas foreign investment. Now, the Zelensky administration is moving to streamline operations and reduce bureaucratic hurdles that previously deterred foreign investors. Ownership of the Olesskaya production sharing agreement (PSA) was transferred in April 2025 from government holding company Nadra Ukraine to Ukraine's largest oil and gas producer, Ukrnafta. The move signalled a strategic shift in the country's approach to fracking, particularly in the Oleska block. Ukrnafta is a state-owned enterprise following the nationalisation of strategic industries and declaration of martial law in 2022, which remains in force to this day. Attracting significant private capital into Ukrainian shale exploration would normally be impossible under these circumstances. However, the source said there are laws in place to ensure they can be overwritten. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Yahoo
an hour ago
- Yahoo
European Market Insights: genOway Société anonyme And 2 Promising Penny Stocks
The European market has shown resilience with the pan-European STOXX Europe 600 Index rising by 0.90%, buoyed by a slowdown in inflation and easing monetary policy from the European Central Bank. As investors navigate these evolving conditions, penny stocks—often representing smaller or newer companies—continue to capture interest for their potential growth at accessible price points. Despite being an outdated term, penny stocks remain relevant as they can offer opportunities for those seeking to invest in financially strong companies with promising prospects. Name Share Price Market Cap Financial Health Rating Mistral Iberia Real Estate SOCIMI (BME:YMIB) €1.01 €22M ★★★★★☆ KebNi (OM:KEBNI B) SEK1.996 SEK541.22M ★★★★★★ Angler Gaming (NGM:ANGL) SEK3.61 SEK270.7M ★★★★★★ Cellularline (BIT:CELL) €2.95 €62.22M ★★★★★☆ Fondia Oyj (HLSE:FONDIA) €4.78 €17.87M ★★★★★★ Abak (WSE:ABK) PLN4.00 PLN10.78M ★★★★★★ Bredband2 i Skandinavien (OM:BRE2) SEK2.38 SEK2.28B ★★★★☆☆ Hifab Group (OM:HIFA B) SEK3.62 SEK220.24M ★★★★★★ Deceuninck (ENXTBR:DECB) €2.175 €300.29M ★★★★★★ Netgem (ENXTPA:ALNTG) €0.936 €31.34M ★★★★★★ Click here to see the full list of 447 stocks from our European Penny Stocks screener. Let's dive into some prime choices out of the screener. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: genOway Société anonyme is a biotechnology company that develops and commercializes custom genetically modified mouse, rat, and cell line models globally, with a market cap of €31.44 million. Operations: The company's revenue is derived entirely from its biotechnology segment, amounting to €27.53 million. Market Cap: €31.44M genOway Société anonyme, with a market cap of €31.44 million, has shown consistent revenue growth, reporting €22.06 million in sales for 2024, up from €20.05 million the previous year. The company maintains strong financial health with short-term assets exceeding both its short and long-term liabilities and a satisfactory net debt to equity ratio of 3.4%. Despite not outperforming the biotech industry in earnings growth last year, genOway's profitability has improved over five years at an impressive annual rate of 67.1%, supported by high-quality earnings and stable weekly volatility at 6%. Click here and access our complete financial health analysis report to understand the dynamics of genOway Société anonyme. Learn about genOway Société anonyme's historical performance here. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Kudelski SA, with a market cap of CHF67.34 million, offers digital access and security solutions for digital television and interactive applications across Switzerland, the United States, France, Germany, Austria, and other international markets. Operations: The company's revenue is primarily derived from three segments: Digital TV ($227.83 million), Cybersecurity ($108.47 million), and Internet of Things ($47.43 million). Market Cap: CHF67.34M Kudelski SA, with a market cap of CHF67.34 million, operates in digital access and security solutions across multiple markets. Despite being unprofitable with increasing losses over the past five years, it holds strong financials with short-term assets exceeding liabilities and more cash than debt. The seasoned management team and board bring stability, while recent partnerships in IoT and AI sectors highlight strategic growth efforts. Notably, Kudelski's collaboration with Stotz Equipment enhances asset visibility solutions without subscription fees, potentially driving future revenue streams within diverse industries like agriculture and construction. The stock trades significantly below estimated fair value compared to peers. Navigate through the intricacies of Kudelski with our comprehensive balance sheet health report here. Evaluate Kudelski's prospects by accessing our earnings growth report. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: PCC Exol S.A. manufactures and distributes surfactants both in Poland and internationally, with a market cap of PLN452.76 million. Operations: The company's revenue is primarily derived from its Specialty Chemicals segment, totaling PLN996.33 million. Market Cap: PLN452.76M PCC Exol S.A., with a market cap of PLN452.76 million, shows promising financials as its short-term assets exceed both long-term and short-term liabilities. The company's earnings growth of 23.1% over the past year surpasses its five-year average and outpaces the broader Chemicals industry growth rate. However, while interest payments are well covered by EBIT, operating cash flow covers only 17% of debt, indicating potential liquidity concerns. Despite a high net debt to equity ratio of 54.1%, PCC Exol maintains high-quality earnings with no significant shareholder dilution recently and offers a price-to-earnings ratio below the Polish market average. Get an in-depth perspective on PCC Exol's performance by reading our balance sheet health report here. Explore historical data to track PCC Exol's performance over time in our past results report. Take a closer look at our European Penny Stocks list of 447 companies by clicking here. Interested In Other Possibilities? These 18 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTPA:ALGEN SWX:KUD and WSE:PCX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Medscape
an hour ago
- Medscape
Study Supports Follow-Up Consultations After Heart Failure
About 40% of patients with diagnosed heart failure did not pursue future cardiology consultations, regardless of the initial severity of their condition. A single follow-up cardiology visit can reduce 1-year all-cause mortality by 6%-9%, with additional visits showing increased benefit as the severity of heart failure increases. METHODOLOGY: A nationwide cohort study included 655,919 French patients (median age, 80 years; 48% women) diagnosed or hospitalized with heart failure between January 1, 2015, and December 31, 2019, and who were still alive on January 1, 2020. Researchers categorized patients into four groups: Those hospitalized with heart failure within the past year, those hospitalized with the condition between 1 and 5 years prior, patients not hospitalized but who were receiving loop diuretics, and patients who were not hospitalized and were not taking loop diuretics. TAKEAWAY: The 1-year risk for all-cause mortality ranged from 8% in patients without hospitalization or use of loop diuretics to 25% for those hospitalized for heart failure within the past year. Mortality risk increased progressively across groups, with an adjusted hazard ratio of 1.61 for patients using loop diuretics, 1.83 for patients using loop diuretics and hospitalized over 1 year prior, and 2.32 for patients hospitalized less than 1 year prior ( P < .0001 for all). < .0001 for all). A single cardiology consultation was associated with a 6%-9% absolute reduction in 1-year all-cause mortality across all groups. The optimal follow-up strategy varied by risk group: One annual visit for low-risk patients, two to three visits for intermediate-risk patients, and four visits for high-risk patients recently hospitalized with heart failure. IN PRACTICE: 'Despite having an HF diagnosis, 40% of patients do not see a cardiologist annually, regardless of disease severity. Simple stratification based on hospitalization history and diuretic use effectively predicts outcomes. Tailoring the annual number of [heart failure] consultations according to this stratification could optimize resource use and reduce avoidable modelled deaths,' the researchers wrote. 'This group represents a significant opportunity to improve survival outcomes with only a modest increase in the total number of consultations. Healthcare systems could formally assess the impact of this annual consultation through large-scale cluster trials, allowing for an evaluation of the broader population-level benefits of this approach,' they added. SOURCE: The study was led by Guillaume Baudry, MD, of the Université de Lorraine in Nancy, France. It was published online in the European Heart Journal and presented at the Heart Failure Association of the European Society of Cardiology (HFA-ESC) 2025 meeting. LIMITATIONS: Researchers excluded patients residing in nursing homes due to their advanced prognosis and unavailability of healthcare utilization data, which may have led to an underestimation of morbidity and mortality. The study did not include heart failure patients who had not been recently hospitalized and did not submit long-term condition paperwork. Important clinical data such as ejection fraction, heart failure phenotype, and prognostic biomarker values were unavailable. DISCLOSURES: The researchers reported receiving fees and grants and other relationships with various pharmaceutical companies including Abbott, AstraZeneca, Bayer, and Pfizer.
